intensive care unit. Our results confirm that it provides satisfactory sedation in patients requiring mechanical ventilation with a range of severity of illness as determined by their APACHE II scores. The degree of sedation with isoflurane was easily and rapidly controlled by changing the inspired isoflurane concentration delivered to the patient. The effective dose of isoflurane for sedating ventilated patients in the intensive care unit was confined to a narrow range (0-1-0-4% concentration), whereas the requirement for midazolam showed considerable variability between patients (0-014-0-140 mg/kg/h). Patients sedated with isoflurane were often tranquil and cooperative, whereas those sedated with midazolam were often confused and disruptive, requiring increasingly higher infusion rates that resulted in oversedation. Provided that patients were not hypovolaemic, isoflurane or midazolam sedation did not have deleterious effects on haemodynamic stability.
In conclusion, isoflurane in subanaesthetic concentrations (0 1-0-6%) provides a useful alternative technique for sedation of ventilated patients in the intensive care unit. It has many advantages over conventional intravenous sedative agents. The quality of sedation and speed of recovery from sedation are significantly better with isoflurane than midazolam. Further studies are required to assess the side effects of prolonged isoflurane sedation.
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Subjects and methods
The machines, which were unlabelled, were placed on a table, and the patient sat on a chair and breathed through a vented anaesthetic mask. Some machines were set at 43°C and others at 30°C; the mean temperatures of the nasal mucosa were 43°C and 33°C, respectively. Both machines gave the sensation of breathing warm, moist air. Other aspects of the administration and assessment were carefully double blinded.
General practice study-Patients came to the Adelaide Centre, Andover, in response to circulars and advertisements, and one of us (JA) took a simple history, asking particularly for any serious underlying disease, chronic or recurrent respiratory infections, respiratory allergies such as hay fever and asthma, and other allergies. Patients whom he thought had true common colds were admitted to the trial. The diagnosis was made on the basis of a short history and presence of typical symptoms, such as runny nose, stuffiness, sore throat, cough, and headache. All the subjects were adults and signed the consent section of a record form, and the full protocol of the trial was approved by Winchester ethical committee. Patients were allocated to treatment by reference to a list of random numbers and inhaled on one occasion for 20 minutes under observation. They were seen immediately after treatment by a doctor, who asked about adverse effects and recorded whether their symptoms were the same, better, or worse. They recorded the severity of their symptoms daily for the next five days on a form with a four point scale (0 to 3). These forms were returned and used for the analysis.
Volunteer study-Volunteers were recruited to the common cold unit in Salisbury, housed in isolation, and observed as previously described. (table II) ; there were similar small differences in the response of other symptoms to the two treatments. During the subsequent days the mean symptom scores were substantially lower in the group given air at 43°C, the mean total scores being 9-3 and 25 9, respectively.
As the group given air at 30°C had had significantly more symptoms than the group given air at 43°C on admission to the trial the significance and size of the beneficial effect might have been overestimated by a simple analysis. We therefore performed a rank analysis of variance. This gave a valid statistic, although the symptom scores were not normally distributed, and we also "blocked" for the scores before treatment. The differences were highly significant (fig 1) . We allowed approximately for the differences in numbers of symptoms before treatment by "correcting" the total score (25 9 x (2 6/3 4) = 19-8), suggesting that the scores of the treated group were reduced to 47% (9-3/19-8) of those expected.
The subgroups with only nasal symptoms were analysed separately, and, though the numbers were small, the initial illnesses were comparable. The mean total scores were 12-3 after treatment with air at 30°C and 7-7 after treatment at 43°C (p<005), representing a reduction of 37%, and the differences in the mean daily scores were also significant (fig 2) . We also looked at the day on which no symptoms were recorded, which was assumed to be the end of the cold. On the fourth day of observation 21 (47%) of the group given air at 43°C had a symptom score of zero, whereas only 1 (2%) of the group given air at 30°C did.
We concluded that, in spite of the imbalance of the study groups, local hyperthermia for 20 minutes had improved the course of the colds, though the effect was less than that reported earlier. On the other hand, 0I--0 300C (table III) . The difference in the proportions of the groups of volunteers who showed improvement was significant (61% (95% confidence interval 31% to 91%)). Figure 3 shows the subsequent courses of the colds as indicated by mean total daily symptom scores and the mean weights of daily nasal secretions. The scores of the two groups were similar on the day of treatment and were subsequently reduced by about 20% in those treated at 43°C; likewise the weights of secretion were reduced by a maximum of 42% after two days. By simple rank analysis these differences were not significant; when "blocked" by the initial weight of nasal secretions (allowing for the fact that on entry to the trial some volunteers had worse colds than others), however, they reached significance on several days. The difference in mean total score was significant (14 v 24, p=0 02, one tail test) as was the difference in mean total weight of secretions (26 v 33, p=0027), these reductions being 43% and 21%, respectively.
By contrast there were no differences in the proportion of volunteers shedding the virus between the two groups after treatment, although the proportion was lower, though not significantly so, on the day of treatment in the group given air at 43°C (fig 3, bottom) . The frequency of antibody response (5/14 at 43°C and 7/13 at 30°C) and the mean titres in convalescence a)*
(1/3-7 v 1/8-0) were also not significantly different.
'°0
Some volunteers mentioned local discomfort in the first few minutes of treatment at 43°C. Although (n=45) volunteers were encouraged to report freely and were examined daily, there was no indication of adverse * effects from the treatment. We wanted to establish whether shorter treatments would yield the same results, so a similar study was done with a modified scheme in which volunteers received 20 minutes of treatment on the day of diagnosis and a further 10 minutes each morning until the symptoms resolved or the trial ended. In this case no continued improvement was seen.
Discussion
The main purpose of these studies was to show impartially whether local hyperthermia benefits colds. We believe that we found evidence for this in two quite different groups of subjects and with different designs of trial. Furthermore, our subjects found the treatment acceptable and the amount of benefit was clinically important.
In our first study (general practice study) we treated naturally acquired colds, most of which had been present for over a day; in the second and third studies (volunteer studies) we treated colds that had been present for only a few hours and caused by a single type of rhinovirus. In the first study we relied on subjective self reporting (though we have evidence that this gives results similar to those obtained by a trained independent observer (S Macintyre, in preparation)). In the second and third we also used a trained doctor and an objective measure of disease-that is, weight of daily nasal secretions. All three trials had weaknesses: in the first randomisation generated groups with disease in which the prevalences of symptoms were different; in the second and third the numbers were small for practical reasons.
In spite of this the trials showed some immediate subjective benefit, and in the second study this was clearly greater with air at 43°C than 30°C. The first two studies showed a clinical advantage for those treated at 43°C, and this continued for two or three days and was confirmed by our most objective measure. The amount of benefit could not be measured exactly, but symptoms and signs were reduced by up to 40%. Interestingly, a recent independent study in Israel with an improved Rhinotherm apparatus showed that two treatments of 20 minutes given to patients with natural colds reduced another objective variable, nasal airway resistance, by about a third for several days.7 Thus, though we cannot support the claim that 80% of people with a cold recover by the day after treatment,2 we believe that three separate satisfactory trials have now shown that colds are improved for several days after treatment and that this is clinically and statistically significant. There is also immediate relief of symptoms, which may be better ifthe machine is run at 43°C rather than at 30°C. In clinical practice there would probably also be a useful placebo effect, and some patients would probably start to treat a mild cold that was going to improve anyway. We therefore find plausible the results of an uncontrolled trial which showed that about 80% of subjects reported that their colds were considerably improved the day after 20 Prolonged respiratory hyperthermia has been used to raise the body core temperature after accidental and experimental immersion in cold water and has been free of unwanted effects' (J S Hayward, personal communication). We did not observe any adverse effects in the subjects taking part in these controlled studies or in others treated under uncontrolled conditions. Nevertheless, a watch should be kept for reactions, perhaps in the few patients who are sensitive. Also, some people may derive more immediate benefit than others. These uncontrolled observations have also suggested benefit in conditions such as asthma and chronic sinusitis so controlled studies are needed on these indications too. Lwoff (personal communication) believes that more dramatic results are obtained if air is insufflated into the nose rather than breathed in from a mask; this idea is also worth further study.
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